Positiv
●
Seeking Alpha
●
vor 6 Monaten
Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies positions it for multiple launches between 2026–2028, supporting long-term growth. Financial strength is evident with $12B in cash, upgraded 2025 revenue guidance ($11.9B–$12B), and accelerating com...